Dermatitis, Atopic: Clinical Trials

11 trials for Dermatitis, Atopic, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

11 active not recruiting. 11 Phase 3, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 3	11	Active not recruiting 11
Phase 2	1	Active not recruiting 1

Follow Dermatitis, Atopic: new trials by email Literature Review of Dermatitis, Atopic trials Research Report on Dermatitis, Atopic

Trials (filtered) newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis Ruxolitinib, Vehicle Cream - Atopic Dermatitis	Phase 3	Active not recruiting	Incyte Corporation	159	2025-06-17	2026-08-19
Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis Placebo, Upadacitinib - Atopic Dermatitis	Phase 3	Active not recruiting	AbbVie	99	2024-12-22	2026-02-23
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis Upadacitinib, Dupilumab - Atopic Dermatitis	Phase 3	Active not recruiting	AbbVie	699	2024-08-19	2026-10-16
Study of CM310 in Adolescent Subjects With Atopic Dermatis CM310 - Atopic Dermatitis	Phase 3	Active not recruiting	Keymed Biosciences Co.Ltd	180	2024-08-02	2025-10-02
A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis Lebrikizumab, Placebo - Dermatitis, Atopic, Eczema	Phase 3	Active not recruiting	Almirall, S.A.	520	2024-07-03	2026-04-21
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab Upadacitinib 15mg Dose, Dupilumab 300mg Dose, Upadacitinib 30mg Dose - Atopic Dermatitis	Phase 3	Active not recruiting	AbbVie	184	2024-06-14	2026-10-16
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis Amlitelimab, Placebo - Dermatitis Atopic	Phase 3	Active not recruiting	Sanofi	1541	2024-05-08	2026-07-10
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor Amlitelimab, Placebo, Topical corticosteroids - Dermatitis Atopic	Phase 3	Active not recruiting	Sanofi	464	2024-02-29	2026-10-13
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis Lebrikizumab, Placebo, Topical Corticosteroid (TCS) - Atopic Dermatitis, Eczema	Phase 3	Active not recruiting	Eli Lilly and Company	377	2022-10-18	2026-07-30
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials Amlitelimab, Topical corticosteroids, Topical calcineurin inhibitors - Dermatitis Atopic	Phase 2 / Phase 3	Active not recruiting	Sanofi	1856	2022-08-22	2026-10-13
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis Placebo, Upadacitinib, Topical corticosteroids (TCS) - Atopic Dermatitis	Phase 3	Active not recruiting	AbbVie	1533	2018-08-09	2025-12-23

Narrower conditions

Broader conditions

Interventions

Sponsors

Countries

Results publications

NIH funding